The invention relates generally to medical devices to remove excess blood from congested tissue and particularly to a simple mechanical device to replace medicinal leeches.
A potential post-surgical complication of reconstructive or microvascular surgery is venous congestion. Replanted tissue may become congested due to blood clot formation in the venous outflow of the tissue, or in any situation where arterial inflow exceeds venous outflow. Furthermore, venous stasis or pooling caused by an arterial supply, which is insufficient for the reconstructed tissue can also occur following microvascular surgery. Venous congestion, if not corrected by surgery or some other means, can result in tissue death.
If surgical correction fails, the current method of treating either venous congestion or venous stasis is with live medicinal leeches. The use of leeches can present a number of problems. For example, leeches can move off congested tissue and feed on normal skin, they are difficult to use in or near orifices of the body because of their potential for migration, the quantity of blood removable by a leech is very limited, and leeches may harbor serious pathogens.
Cursory attempts have been made to develop mechanical or chemical replacements for the live medicinal leech. A simple mechanical device was used by Smoot et al. in 1995 (Smoot EC, Ruiz-Inchaustegui JA, Roth AC (1995) Mechanical Leech Therapy to Relieve Venous Congestion. J Reconstr Microsurg 11: 51-55). This device consisted of a small glass bell that was placed over a punch biopsy wound. A fluid passing through an inlet port irrigated the wound and was suctioned off via a suction port at −80 mmHg. Chemical replacements for leech therapy have also been studied. The “chemical leech” involved subcutaneous injections of calcium heparin into the reattached fingers of three patients, with drainage into dressings over the surgical site. (Barnett G. R., Taylor G.I. and Mutimer K.L. (1989). The “chemical leech:” Intra-replant subcutaneous heparin as an alternative to venous anastomosis. Report of three cases. Br J Plast Surg 42:556-558. These subcutaneous injections of anticoagulant were used to promote drainage of excess blood into the dressings of the surgical site. However, prior work has not provided an adequate clinical solution for the post-surgical complication of venous congestion. The need for the development of new techniques is clearly indicated.
The present invention provides an improved device for the treatment of venous congestion. In one non-limiting embodiment, the device consists of a shell, which acts as a collection chamber and which supports a conduit terminating in a widened delivery tip which supplies anticoagulant subcutaneously through a skin incision.
Specifically, the invention provides a shell having a rim adapted to abut the patient's skin to define a suction area circumscribed by the rim and enclosed by an inner volume of the shell. A conduit is supported by the shell having a delivery tip for the delivery of anticoagulant and saline irrigation positionable subcutaneously below the rim within the suction area when the shell is positioned against the patient's skin, the delivery tip having a larger cross-sectional area than the conduit to disperse the anticoagulant beneath the skin and provide subcutaneous agitation as a means of discouraging or breaking up clot formation. A suction port is attached to the shell through which recovered anticoagulant and blood may be drawn from the inner volume.
Depending on the embodiment, the delivery tip may 1) supply anticoagulant subcutaneously in a controlled fashion, 2) disperse the anticoagulant, 3) provide mechanical anticoagulation by automated rotational and vertical movement of the delivery tip, 4) provide subcutaneous tenting so as to create a subcutaneous pocket and keep open (apart) the skin incision edges, 6) provide mechanical abrasion to the wound edges, 7) irrigate the wound. Suction is applied to the shell via an outflow port allowing recovered blood and anticoagulant/irrigant to be withdrawn from the inner chamber.
It is one object of the invention to provide for improved removal of blood from congested tissue through the combination of subcutaneous delivery of anticoagulant and topical recovery.
The device may include an air inlet port allowing the introduction of air into the inner volume and down to the skin surface. Thus, it is another object of the invention to both provide a path of air entry to the skin surface. This air flow will create turbulence in the irrigant flowing through the shell at the skin surface, thus creating mechanical anticoagulation at the skin surface and elsewhere within the shell preventing clot formation.
The device may include a sensor detecting blood volume outflow via the use of weight measurements of the inflow and outflow fluids or optical sensor measurement of outflow concentration.
Thus, it is another object of the invention to provide for semiautomatic operation in which a sensor provides an indication to the operator of successful operation or trigger sequences of agitations and air and liquid flows to provide for efficient blood removal.
The foregoing objects and advantages may not apply to all embodiments of the inventions and are not intended to define the scope of the invention, for which purpose claims are provided. In the following description, reference is made to the accompanying drawings, which form a part hereof, and in which there is shown by way of illustration, a preferred embodiment of the invention. Such embodiment also does not define the scope of the invention and reference must be made therefore to the claims for this purpose.
Referring now to
At the apex of the shell 12 is an opening 18 surrounded by a cylindrical sleeve 20. The sleeve 20 is sized to receive along axis 16, a conduit 22, the latter being preferably a stainless steel tube having a height greater than that of the shell 12. The conduit 22 may freely rotate within the sleeve 20, but blocks the opening 18 to prevent passage of air or liquid into or out of the opening 18 except through the conduit 22.
Referring now also to
A cross incision 28 made in the skin 30 of a patient permits insertion of the delivery tip 24 subcutaneously with the conduit 22 extending upward out of the incision 28. Before insertion of the delivery tip 24′ into the incision 28, a small volume bolus of anticoagulant may be administered including possibly other agents such as vasodilators. The portion of the conduit 22 extending out of the incision 28 is received by the sleeve 20 so that the shell 12 moves downward to abut the skin 30 and cover the cross incision 28. The diameter of the rim 14 of the shell 12, in the preferred embodiment, is approximately 1.3 centimeters.
The conduit 22 may be attached at its upper end protruding from the sleeve 20 to an anticoagulant supply hose 46 delivering concentrated heparin or other anticoagulant or thrombolytic substance (such as streptokinase) through the conduit 22 into the microporous delivery tip 24 for diffusion subcutaneously in the surrounding area.
Extending radially near the rim 14 of the shell 12 outside of the shell 12 is an exhaust port 31 sized to receive a suction hose 32 and providing an exhaust path indicated by arrow 34 in
An air inlet port 38 extends vertically upward from a top of the shell 12 to receive an air supply hose 42 and to communicate air therefrom through the shell 12 to a central air tube 40 extending downward within the shell to a point immediately above the surface of the skin 30. Ideally the opening of the tube 40 is slightly below the opening of the exhaust port 31 so as to ensure the tip of the air inlet port 38 is immersed in any unexhausted effluent liquid 44.
Similarly, an irrigation port 52 extends vertically upward from a top of the shell 12 opposed to the air inlet port 38 about the sleeve 20 to receive an irrigation hose 50 and to communicate irrigation liquid therefrom through the shell 12 to an irrigation tube 54 similar to the air tube 40 extending downward within the shell to a point immediately above the surface of the skin 30. Tubes 40 and 54 may be stainless steel hypodermic needle tubes.
Referring still to
Anticoagulant supply hose 46 is then attached to the portion of the conduit 22 extending out of the shell 12 through sleeve 20, while hoses 32, 42, and 50 may be pre-attached to the shell 12.
Concentrated Heparin, or other substance, is next delivered through the conduit 22 into the microporous delivery tip 24 for diffusion subcutaneously in the surrounding area. Encouraged by the anticoagulant, blood in the region of the delivery tip 24 is drawn up through the incision 28. The extracted blood and anticoagulant then mixes with the irrigant introduced through tube 54. The irrigant is preferably a wash of dilute anticoagulant and saline solution and serves to further inhibit the formation of clots in the resulting effluent liquid 44.
Air entering through an air supply hose 42 through the tube 40 percolates air bubbles through effluent liquid 44, the bubbles serving further to inhibit the formation of clots on the incision surface. Pulsations of pressure, air, and irrigant may also be used to improve blood flow.
Periodically, the conduit 22 is rotated in alternate directions to reduce the formation of clots around the delivery tip 24. The disk shape and its orientation perpendicular to the axis of rotation facilitate this rotational process.
Anticoagulant, irrigation, airflow, and suction are balanced to establish a slight negative pressure within the shell 12 with respect to ambient pressure. The delivery of air, saline and anticoagulant and the application of suction may be performed by an automated control system comprising pumps and pressure transducers and a programmed controller according to techniques well known in the art.
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
As before, the anticoagulant supply hose 46 attaches to conduit 22 to deliver anticoagulant to delivery tip 24′.
Air supply hose 42b provides air to bellows actuator 70 having one portion attached to the shell 12 and the other portion attached to the conduit 22 to cause axial motion 77 of the conduit 22 under varying air pressure from air supply hose 42b. The axial motion moves delivery tip 24 into and out of the incision to reduce clot formation and to promote bleeding by tenting or flexing of the edges of the incision 28 with the upper part of the delivery tip 24 as will be described. The tenting effect keeps the edges of the wound separated allowing the irrigant to irrigate the entire wound and flow freely to the skin surface.
Air supply hose 42c provides air to a rotary actuator 74 having an internal vane 76 attached to the conduit 22 to provide rotary motion 78 of the conduit 22 back and forth about its axis. These two motions 77 and 78 may be combined to produce a spiraling up and down motion further preventing clot formation.
Referring now to
The delivery tip may be constructed of a biologically inert material such as Teflon and attached to the conduit 22 so that its point extends through the incision 28. The wedge shape of the delivery tip 24′ plus the up and down reciprocal action 72 flexes the edges of the incision 28 laterally in and out so as to prevent clot formation and promote bleeding.
Extending upward from the lower base of the delivery tip 24′ are grooves providing axial abrading edges 82. The rotational movement 78 causes the axial abrading edges 82 to disrupt clot formation and further abrade and promote bleeding.
Referring now to
Referring now to
Air may be provided from a pressurized hospital source 92 or via a self contained pump 94 communicating with room air. The air feeding air supply hose 42a is micro-filtered by filter 99 to provide a sterile air stream for agitation of the removed anti-coagulant and blood as has been described. This in turn allows for autotransfusion of the recaptured blood as will be described. Air supply hoses 42b and 42c need not be filtered provided their associated actuators 70 and 74 do not exhaust air into the shell 12.
Each of the air supply hoses 42a, 42b, and 42c pass through electrically controllable valves 96 allowing air flow to be metered by microprocessor 100. The valves 96 on air supply hoses 42b and 42a allow control of the motion of the conduit in rotation and axial translation such as may optimized to minimize damage and maximize the therapeutic effect of this motion. As will be described, this motion may be controlled according to the flow of blood and anticoagulant back to the controller 62 to create a control closed loop system.
Anticoagulant may be provided from an IV bag 104 such as may be hung on the IV pole flowing under gravity or pumped by internal pump 102 controlled by the microprocessor 100. The anticoagulant passes through a metering valve 110 (or is controlled by a metering pump 102) allowing the microprocessor 100 to control flow of anticoagulant to the anticoagulant supply hose 46.
Suction for the suction hose 32 may come from an internal suction pump 112 or may be provided by a connection to the hospital vacuum line 114. The suction hose 32 passes through a flow meter 106 measuring the flow of returned anticoagulant and blood such as may provide a signal to the microprocessor 100 to control the amount of agitation by means of air supply hoses 42b and 42c as described above. Ideally, the rate of change of blood volume over time is used to determine the frequency of the actuation.
The returned blood and anticoagulant may-be collected in a reservoir 116 attached to the IV pole for later autotransfusion.
In the preferred embodiment, the controller 62 monitors on a continuous basis, the amount of blood and anticoagulant removed from the incision as measured by the flow meter 106 or by a weighing system employing well known strain gauge or other type of weighing systems. The amount of blood alone may be determined by subtracting the amount of anticoagulant delivered by anticoagulant supply hose 46 through metering valve 110 and this information is displayed to the operator to provide a quantitative indication of the correct operation of the device 10′.
The controller 62 may include a battery 118 and/or provision for connection to a low voltage cabling to a transformer attached to the hospital line voltage.
It is specifically intended that the present invention not be limited to the embodiments and illustrations contained herein, but that modified forms of those embodiments including portions of the embodiments and combinations of elements of different embodiments also be included as come within the scope of the following claims.
This application is a continuation in part of U.S. application Ser. No. 09/745,298 filed Dec. 20, 2000 which is based on and claims the benefit of U.S. provisional application 60/171,351 filed Dec. 22, 1999.
Number | Name | Date | Kind |
---|---|---|---|
5156597 | Verreet et al. | Oct 1992 | A |
5531672 | Lynn | Jul 1996 | A |
6156004 | Tremaine et al. | Dec 2000 | A |
6227203 | Rise et al. | May 2001 | B1 |
6340354 | Rambin | Jan 2002 | B1 |
6689103 | Palasis | Feb 2004 | B1 |
6878142 | Lawrence et al. | Apr 2005 | B2 |
Number | Date | Country |
---|---|---|
WO 0078212 | Dec 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20030032919 A1 | Feb 2003 | US |
Number | Date | Country | |
---|---|---|---|
60171351 | Dec 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09745298 | Dec 2000 | US |
Child | 10273215 | US |